Strongyloides Antibody, IgG by ELISA
| Label Mnemonic: | STRONGY |
| Epic code: | LAB4099 |
| Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Serum
Collection Medium:
 |
| Red top tube 5 mL (Clot Activator) |
Minimum:
Preferred Minimum: 1.0 mL serum in red top tube
Absolute Minimum: 0.3 mL serum in red top tube
Absolute Minimum: 0.3 mL serum in red top tube
Rejection Criteria:
Bacterially contaminated, heat-inactivated, hemolyzed, icteric, or
lipemic specimens.
Turn Around
Time:
1-3 days upon receipt at reference laboratory
Reference Range:
0.9 IV or less Negative - No significant level of Strongyloides IgG antibody detected. 1.0 IV Equivocal - The Strongyloides IgG antibody result is borderline and therefore inconclusive. Recommend retesting the patient in 2-4 weeks, if clinically indicated. 1.1 IV or greater Positive - IgG antibodies to Strongyloides detected, which may suggest current or past infection.
Interpretive Data:
False-positive results may occur with prior exposure to other helminth
infections. Testing low-prevalence populations may also result in
false-positive results.
Test
Limitations:
This assay should be used to aid in the diagnosis and confirmation of
patients in which there is a clinical suspicion of Strongyloides
infection. Results for this test should not be used without
correlation to clinical history or other data.
This assay will detect the presence of serum IgG antibodies against Strongyloides species. While diagnosis may be made clinically, serologic antibody testing can aid in the diagnosis of Strongyloidiasis. However, cutaneous larva migrans is observed with infections by other nematodes such as Ancylostoma species, Uncinaria stenocephala, and Bunostomum phlebotomum. Additionally, antibody cross-reactions in patients with filariasis may occur.
The enzyme immunoassay for Strongyloides antibody detection is recommended in place of IFA or IHA due to its sensitivity, which ranges from 84-92 percent. However, eight to 16 percent of individuals infected with Strongyloides are seronegative, so false-negative results cannot be ruled out. Additionally, since this assay measures Strongyloides-specific IgG in patient samples, test results from single samples cannot be used to differentiate between current and past infections.
This assay will detect the presence of serum IgG antibodies against Strongyloides species. While diagnosis may be made clinically, serologic antibody testing can aid in the diagnosis of Strongyloidiasis. However, cutaneous larva migrans is observed with infections by other nematodes such as Ancylostoma species, Uncinaria stenocephala, and Bunostomum phlebotomum. Additionally, antibody cross-reactions in patients with filariasis may occur.
The enzyme immunoassay for Strongyloides antibody detection is recommended in place of IFA or IHA due to its sensitivity, which ranges from 84-92 percent. However, eight to 16 percent of individuals infected with Strongyloides are seronegative, so false-negative results cannot be ruled out. Additionally, since this assay measures Strongyloides-specific IgG in patient samples, test results from single samples cannot be used to differentiate between current and past infections.
Methodology:
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
CPT Code:
86682